Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

Abstract Background Being the standard-of-care for four decades, cisplatin-based chemotherapy is highly efficient in treating germ cell tumors (GCT). However, often refractory patients present with a remaining (resistant) yolk-sac tumor (YST(-R)) component, resulting in poor prognosis due to lack of...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Margaretha A. Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2023-03-01
Sarja:	Molecular Medicine
Aiheet:	Germ cell tumors Yolk-sac tumor Therapy Resistance CLDN6 Antibody-drug-conjugate
Linkit:	https://doi.org/10.1186/s10020-023-00636-3
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!